findmyKOL
Clinical trialNCT02359019CompletedPhase 2Interventional

MK-3475 as Maintenance Therapy in Extensive Stage SCLC

SponsorBarbara Ann Karmanos Cancer InstituteEnrollment45Extensive Stage Small Cell Lung Carcinoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial studies how well pembrolizumab works in treating patients with extensive stage small cell lung cancer after completion of combination chemotherapy. Pembrolizumab may be effective in controlling small cell lung cancer for a longer period of time in patients with responsive or stable disease after completion of combination chemotherapy.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Rush University Medical Center

    Chicago, Illinois, United States

  • University of Michigan

    Ann Arbor, Michigan, United States

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan, United States

  • Cleveland Clinic

    Cleveland, Ohio, United States

  • Penn State Milton S. Hershey Medical Center

    Hershey, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Pembrolizumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
28 Feb 2015
Primary completion
31 Oct 2018
Completion
31 Oct 2018
Last update posted
14 Oct 2022
Registered enrollment
45
Registry id
NCT02359019
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.